title: Tropisetron vs ondansetron for prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy: a randomized double-blind, placebo-controlled study.
abstract: BACKGROUND
  Postoperative nausea and vomiting are observed in increased frequency after laparoscopic surgery. This study was performed in order to compare the efficacy of two 5-hydroxytryptamine-3 (5-HT3) receptor antagonists, ondansetron and tropisetron, in preventing postoperative nausea and vomiting (PONV) after laparoscopic cholecystectomy.
  
  
  METHODS
  Using a randomized, double-blind study design, 87 ASA I and II patients scheduled for laparoscopic cholecystectomy were randomly assigned to receive 4 mg ondansetron (Group A, n = 29), 5 mg tropisetron (Group B, n = 31), or placebo (Group C, n = 27) intravenously (IV) before induction of anesthesia. The end points evaluated were frequency of nausea, nausea intensity rated on a scale from 1 (mild) to 5 (most severe), frequency of vomiting, and need for rescue antiemetics. These parameters were measured immediately after surgery (0 h), at 3 h, 6 h, and 12 h postoperatively.
  
  
  RESULTS
  The frequency of nausea was significantly higher in group A (31.2%) compared to group B (14%) at 12 h postoperatively (p <0.01). However, patients of group A had significantly lower nausea scores at 3 h postoperatively compared to group B. Postoperative vomiting occurred in 13.8% of patients in group A and 9.6% of patients in group B throughout the whole study period (p = n.s.). The need for rescue antiemetics was similar between groups A and B. Both groups were superior to placebo concerning all studied parameters.
  
  
  CONCLUSIONS
  Our results show that ondansetron may be more effective in controlling nausea intensity during the first 3 h after laparoscopic cholecystectomy, while tropisetron has a longer-acting activity, with a major impact on nausea frequency at 12 h postoperatively.
authors.affiliation: Department of Anesthesiology, G. Gennimatas Hospital, Ethnikis Aminis 41, 546 35 Thessaloniki, Greece.
authors.forename: H
authors.initials: H
authors.lastname: Argiriadou
authors.forename: B
authors.initials: B
authors.lastname: Papaziogas
authors.forename: T
authors.initials: T
authors.lastname: Pavlidis
authors.forename: A
authors.initials: A
authors.lastname: Parlapani
authors.forename: M
authors.initials: M
authors.lastname: Georgiou
authors.forename: P
authors.initials: P
authors.lastname: Papagiannopoulou
authors.forename: T
authors.initials: T
authors.lastname: Papaziogas
mesh_terms: D000328:Adult; D000932:Antiemetics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017081:Cholecystectomy, Laparoscopic / Q000009:adverse effects* / Q000379:methods; D004311:Double-Blind Method; D005260:Female; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D017294:Ondansetron / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D020250:Postoperative Nausea and Vomiting / Q000517:prevention & control*; D012893:Sleep Wake Disorders / Q000139:chemically induced; D000077526:Tropisetron
chemical_list: D000932:Antiemetics; D007211:Indoles; D017294:Ondansetron; D000077526:Tropisetron